QRG Capital Management Inc. Sells 3,177 Shares of Twist Bioscience Co. (NASDAQ:TWST)

QRG Capital Management Inc. lowered its stake in Twist Bioscience Co. (NASDAQ:TWST) by 11.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,345 shares of the company’s stock after selling 3,177 shares during the period. QRG Capital Management Inc.’s holdings in Twist Bioscience were worth $1,131,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TWST. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience in the third quarter worth $34,000. Van ECK Associates Corp boosted its stake in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares in the last quarter. Beaird Harris Wealth Management LLC bought a new position in Twist Bioscience in the 3rd quarter worth about $95,000. Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the last quarter. Finally, KBC Group NV increased its stake in Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after purchasing an additional 1,226 shares in the last quarter.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 3,504 shares of Twist Bioscience stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $51.85, for a total transaction of $181,682.40. Following the completion of the transaction, the director now directly owns 21,641 shares of the company’s stock, valued at $1,122,085.85. The trade was a 13.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 5,200 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now owns 667,318 shares in the company, valued at $32,932,143.30. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,180 shares of company stock valued at $1,821,971 over the last 90 days. 3.01% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on TWST shares. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Finally, TD Cowen reissued a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Trading Down 4.4 %

NASDAQ:TWST opened at $37.11 on Tuesday. The business has a fifty day moving average price of $47.45 and a 200-day moving average price of $45.63. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.98 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm’s revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.75) EPS. Sell-side analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.